Hims & Hers Stock: Growth, Noise, and Where to Focus Now
Hims & Hers Health (HIMS -7.67%) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in this video.
Hims and Hers Health Stock Testing Key Trendline
Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15.
CEO of HIMS dumps over $6 million of stock
Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven't exactly been performing well as of late.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further?
Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust growth in 2024. Shares of the company have risen 43% in the past month, significantly outperforming the industry's growth of 5.5%.
Hims & Hers: Look At What Matters Most
Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS companies in terms of scalability and growth potential. The company reported stellar Q3 FY2024 results with a 77% YoY revenue increase, driven by strong subscriber growth and high retention rates in personal health services. Despite regulatory risks and competition, HIMS' advanced tech platform and focus on personalized healthcare provide a strong foundation for long-term shareholder value.
Options Action: Bearish bets on Hims
Mike Khouw joins 'Fast Money' to talk the options trade around Hims.
Hims & Hers: The Show Must Go On
Hims & Hers Health stock is substantially undervalued despite a massive YTD rally, presenting a strong buy opportunity due to a myriad of catalysts. The company demonstrates exponential revenue growth, improving operating margins, and successful customer acquisition cost reduction, driven by personalized solutions and innovative product formats. HIMS is financially strong with minimal debt and a dominant market share, strategically positioned to leverage AI-driven tools and proprietary systems for growth.
2 Telehealth Stocks That Could Gain from Trump's New FDA Pick
The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University in Baltimore, Maryland, and also serves as the chief medical officer at Sesame, an online telehealth platform.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Driving Growth In Wellness
Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Q3 2024 revenue rose 77% YoY to $401.6M, with $392.6M from online channels (+79% YoY). GLP-1 patient retention at 12 weeks reached 70%, outperforming the industry average of less than 42%.
Why Hims & Hers Stock Jumped on Massive FDA News
Shares of Hims & Hers (HIMS 0.67%) jumped as much as 23% in trading on Monday after President Trump announced his new Food and Drug Administration (FDA) chief, who happens to have ties to a business similar to Hims & Hers. In this video, Travis Hoium covers why this is important and why the stock is moving as fast as it is.
